Growth-differentiation Factor-15 and Tissue Doppler Imaging in Detection of Anthracycline-induced Cardiomyopathy During Therapy of Childhood Cancers

Basit Öğe Kaydı
dc.contributor.authorKaya, Fatma
dc.contributor.authorArslan, Derya
dc.contributor.authorVatansev, Hüsamettin
dc.contributor.authorKöse, Doğan
dc.contributor.authorÇimen, Derya
dc.contributor.authorAkyürek, Fikret
dc.contributor.authorOran, Bülent
dc.date.accessioned2020-03-26T19:24:25Z
dc.date.available2020-03-26T19:24:25Z
dc.date.issued2016
dc.departmentSelçuk Üniversitesien_US
dc.description.abstractObjectives:The aim of this study was to evaluate the importance of growth-differentiation factor-15 (GDF-15) levels and tissue Doppler imaging (TDI) in the early detection of anthracycline-induced cardiomyopathy during the treatment of childhood cancers.Patients and Methods:Twenty patients (13 males and 7 females) newly diagnosed with childhood cancer whose treatment protocol included anthracycline were included in the study. Echocardiography, including M-mode, pulse Doppler, and TDI, was performed after the first anthracycline treatment at cumulative doses of 100, 200, and 300 mg/m(2) and at least 6 months after the last treatment. GDF-15 and troponin-I were also measured at these time points.Results:The median age of the patients was 14 years (range, 3 to 18 y). The median cumulative anthracycline dose was 220 mg/m(2) (range, 60 to 400 mg/m(2)). Conventional pulse wave and pulse wave tissue Doppler methods revealed significant differences in the right ventricular myocardial performance indices of the patients who received cumulative anthracycline doses of 300 mg/m(2) compared with their indices at least 6 months after the last treatment. The serum GDF-15 levels after the cumulative anthracycline dose of 200 mg/m(2) were also higher than the patients' pretreatment levels.Conclusions:Doppler/TDI and GDF-15 levels may be used in the early determination of anthracycline-induced cardiomyopathy during the treatment of childhood cancers.en_US
dc.description.sponsorshipSelcuk University, Scientific Research Projects Coordiantion UnitSelcuk University [12102016]en_US
dc.description.sponsorshipSupported by Selcuk University, Scientific Research Projects Coordiantion Unit (Project Number: 12102016).en_US
dc.identifier.doi10.1097/MPH.0000000000000491en_US
dc.identifier.endpageE112en_US
dc.identifier.issn1077-4114en_US
dc.identifier.issn1536-3678en_US
dc.identifier.issue3en_US
dc.identifier.pmid26907646en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.startpageE107en_US
dc.identifier.urihttps://dx.doi.org/10.1097/MPH.0000000000000491
dc.identifier.urihttps://hdl.handle.net/20.500.12395/33650
dc.identifier.volume38en_US
dc.identifier.wosWOS:000374777900005en_US
dc.identifier.wosqualityQ4en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherLIPPINCOTT WILLIAMS & WILKINSen_US
dc.relation.ispartofJOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGYen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.selcuk20240510_oaigen_US
dc.subjectanthracycline cardiotoxicityen_US
dc.subjectchildrenen_US
dc.subjectgrowth-differentiation factor-15en_US
dc.subjecttissue Doppler imagingen_US
dc.titleGrowth-differentiation Factor-15 and Tissue Doppler Imaging in Detection of Anthracycline-induced Cardiomyopathy During Therapy of Childhood Cancersen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu